The EU Commission conditionally approves an acquisition in the pharmaceutical sector (Pfizer / Hospira)

Elliott, Porter

Previous article The EU Commission clears acquisition of a pharmaceutical company, with effects in the market for biosimilars, subject to remedies that ensure innovation competition (Pfizer / Hospira) Next article The EU Commission clears a merger subject to remedies in the pharmaceutical sector (Pfizer / Hospira)

4 Aug 2015

The EU Commission conditionally approves an acquisition in the pharmaceutical sector (Pfizer / Hospira)

KEYWORDS

Reference

EU Commission, Pfizer / Hospira, Press release, 4 August 2015

On 4 August 2015, the EU Commission approved the acquisition by Pfizer of Hospira, a US-based competitor in, amongst other areas, biosimilar drugs and sterile injectable drugs. In order to obtain approval, Pfizer agreed to a number of divestments designed to eliminate actual or potential overlaps in the parties’ product

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

PDF Version

Author

Porter Elliott
Van Bael & Bellis (Brussels)

Belgium 227 contributions 70752 visits

Quotation

Porter Elliott, The EU Commission conditionally approves an acquisition in the pharmaceutical sector (Pfizer / Hospira), 4 August 2015, e-Competitions Pharma & Mergers, Art. N° 75437

Visites 445